How to Get an ApoB Test. A Step-by-Step Guide.

ApoB is more accurate than LDL-C for predicting cardiovascular events. The 2019 ESC/EAS guidelines named it the preferred lipid target in high-risk patients, and it is not on your standard panel. Getting it requires knowing which path to take and exactly what to say. 5 / Solid

The Mechanism

Every atherogenic lipoprotein particle, whether VLDL, IDL, LDL, or lipoprotein(a), carries exactly one apolipoprotein B molecule on its surface. This means ApoB is a direct count of the total number of atherogenic particles circulating in the blood, not a measure of cholesterol mass.

This distinction matters because LDL-C measures the cholesterol content carried inside LDL particles, not the particle count itself. Two patients can have identical LDL-C values of 110 mg/dL while having substantially different particle counts. The patient with small, dense LDL particles carries far more individual particles per unit of cholesterol mass. Each of those particles can penetrate the arterial wall and initiate atherosclerotic plaque formation. ApoB counts all of them.

The MESA study, which followed 6,814 participants free of cardiovascular disease at baseline for 10 years, found that ApoB was a stronger predictor of incident cardiovascular events than LDL-C, particularly in patients with metabolic syndrome where the discordance between ApoB and LDL-C is greatest. The Emerging Risk Factors Collaboration, pooling data from 68 prospective studies and 302,430 participants, confirmed that ApoB provided stronger cardiovascular risk prediction than non-HDL cholesterol or LDL-C across multiple population subgroups.

The 2019 ESC/EAS dyslipidemias guidelines recommend ApoB as the primary treatment target in patients with metabolic syndrome, diabetes, or very low LDL with residual risk, citing its superior predictive value and the absence of any fasting requirement.

What the Evidence Shows

The case for ApoB over LDL-C rests on several converging lines of evidence. First, Mendelian randomization studies using naturally occurring genetic variants that raise or lower ApoB confirm that it is ApoB particles, not LDL cholesterol mass per se, that cause atherosclerosis. Individuals carrying loss-of-function variants in PCSK9 or APOB genes have dramatically lower ApoB concentrations and markedly fewer cardiovascular events over their lifetimes, supporting a causal rather than correlational relationship.

Second, the discordance between ApoB and LDL-C is not rare. The Canadian Dyslipidemia Working Group estimated that approximately 35 percent of patients classified as low risk by LDL-C alone have elevated ApoB, meaning standard lipid panels systematically misclassify a large fraction of higher-risk patients as lower risk.

Third, studies of statin therapy response show that patients who lower LDL-C substantially but do not achieve proportional ApoB reduction retain elevated residual risk. The JUPITER trial, which enrolled 17,802 patients treated with rosuvastatin, found that on-treatment ApoB was a stronger predictor of residual cardiovascular risk than on-treatment LDL-C, reinforcing its role as a therapeutic target rather than simply a baseline screening marker.

The AMORIS study, a Swedish prospective study of 175,553 participants published in The Lancet in 2001, found that ApoB was a stronger predictor of fatal MI than LDL-C in both men and women. Notably, the ratio of ApoB to apolipoprotein A1 (the primary protein on HDL particles) was among the strongest predictors of fatal MI in the entire study, outperforming every conventional lipid measure tested. The INTERHEART study, a case-control study of 27,098 participants across 52 countries published in The Lancet in 2004, found that the ApoB to ApoA1 ratio was the single most informative lipid marker for first acute MI globally, attributing approximately 54 percent of MI risk to this ratio across all geographic and demographic subgroups.

The practical upshot: ApoB below 90 mg/dL for primary prevention patients at low risk, below 70 mg/dL when significant risk factors are present, and below 55 mg/dL for patients with established cardiovascular disease. These thresholds align with ESC 2019 guidance and are increasingly reflected in the 2022 ACC Expert Consensus on Non-Statin Therapies.

Why the Standard Panel Misses It

The standard lipid panel was developed in the 1970s using the technology available at that time: a colorimetric assay for total cholesterol and a calculated LDL-C derived from the Friedewald equation (LDL-C = Total Cholesterol minus HDL minus Triglycerides divided by 5). The Friedewald equation was validated in a small population under fasting conditions and assumes a fixed ratio between VLDL cholesterol and triglycerides.

That assumption breaks down in patients with elevated triglycerides (above 200 mg/dL), metabolic syndrome, or type 2 diabetes, which are the patients where cardiovascular risk is most likely to be underestimated by LDL-C. In these individuals, triglycerides are elevated, VLDL particle size is small, and the Friedewald equation systematically underestimates LDL-C. More importantly, even a direct LDL-C measurement still misses the particle count. A patient with small, dense LDL particles has more particles per unit of LDL-C than a patient with large, buoyant LDL particles carrying the same cholesterol mass.

ApoB was measurable in the 1970s as well. It was not adopted into standard practice not because of a scientific limitation but because of a workflow and billing infrastructure built around the cholesterol panel. The clinical inertia around this infrastructure is the primary reason ApoB is not on routine panels today, not a lack of evidence for its value.

What to Do This Week

1. At your next lab draw, say: “I would like ApoB added to my lipid panel.” The full clinical name is apolipoprotein B. No fasting is required. It is one additional tube and can be added to any existing blood draw order. The diagnosis codes most likely to generate insurance coverage are E78.5 (hyperlipidemia, unspecified) and Z82.49 (family history of cardiovascular disease). If either applies, say so.

2. If your physician is unfamiliar with ApoB or reluctant to order it, reference the 2019 ESC/EAS guidelines specifically. You can say: “The 2019 European Society of Cardiology guidelines on dyslipidemias designate ApoB as the preferred target in high-risk patients. I would like it included in my cardiovascular risk assessment.” A citation from an international guideline body typically resolves the hesitation.

3. If you want the test before your next physician appointment, use QuestDirect (questdiagnostics.com) or LabCorp OnDemand in your state. Search for “apolipoprotein B” using the full name, as “ApoB” does not always appear in consumer-facing lab portals. Cost without insurance typically runs $30 to 45.

4. If you are in New York state, direct-to-consumer lab ordering is restricted and requires a physician order or a telemedicine provider. Telemedicine platforms including Hims, Roman, and Hone Health can order ApoB as part of a cardiovascular risk consultation in all 50 states, including New York. Rupa Health and Marek Health are physician-mediated platforms that operate in restricted states as well.

5. Once you have your ApoB result, bring it to your physician alongside your LDL-C with the following question: “My LDL-C is [X] and my ApoB is [Y]. Does the relationship between these two numbers change my cardiovascular risk assessment or my treatment plan?” If your ApoB is substantially higher than your LDL-C would predict, that gap is the information your LDL-C alone was not providing.

NMR LipoProfile: The Alternative Particle-Counting Method

Some clinicians, particularly those focused on metabolic health and lipidology, order an NMR LipoProfile instead of or alongside ApoB. Understanding how these tests relate prevents confusion when you encounter a result that uses particle number rather than protein concentration.

NMR LipoProfile, available in the United States primarily through LabCorp’s Vantera analytical platform, uses nuclear magnetic resonance spectroscopy to measure lipoprotein particle concentrations by size. The primary cardiovascular metric it reports is LDL-P, LDL particle number in nanomoles per liter, which reflects approximately how many individual LDL particles are present in the sample. It also provides HDL particle number, particle size distributions for LDL and HDL, and VLDL particle information.

LDL-P and ApoB measure related but not identical things. Because each LDL particle contains exactly one ApoB protein, LDL-P and ApoB should in theory be proportional. In practice, correlation coefficients are in the range of 0.85 to 0.90 in most study populations, meaning they broadly agree but diverge in a meaningful minority of patients. The divergence is most common in metabolic syndrome, where small dense LDL particles are enriched, in this case, LDL-P may be elevated while LDL-C appears normal, and the particle size distribution from NMR can characterize this pattern more granularly than ApoB alone.

The reason ACC/AHA guidelines and the 2022 expert consensus reference ApoB as the preferred particle-level metric rather than NMR LipoProfile is straightforward: ApoB measures total atherogenic particles. This includes not just LDL but also VLDL, intermediate-density lipoprotein (IDL), and lipoprotein(a), all of which are atherogenic and each of which contains exactly one ApoB. LDL-P from NMR captures only LDL particles and misses the VLDL and IDL contribution, a meaningful gap in patients with hypertriglyceridemia or significant residual VLDL burden.

ApoB is also simpler to perform, does not require fasting for the protein measurement itself, costs approximately $25 to $40 without insurance, and is available at any major reference laboratory. NMR LipoProfile typically costs $80 to $150 without insurance and requires a fasting sample for the particle size and VLDL measurements to be interpretable.

If a clinician you work with uses NMR LipoProfile, the LDL-P target that corresponds to ApoB below 70 mg/dL is generally considered LDL-P below 1,000 nmol/L for primary prevention with significant risk factors, and approximately 700 nmol/L for secondary prevention, though these are approximations given the correlation rather than exact equivalence between the two metrics.

Interpreting What You Get

The number you receive needs a frame of reference grounded in outcome data, not lab reference ranges. Standard lab reports flag ApoB above the 95th or 99th percentile for the general population, which does not correspond to the therapeutic targets derived from cardiovascular outcome trials.

The ESC 2019 and ACC 2022 expert consensus thresholds are the ones to use:

ApoB below 90 mg/dL is appropriate for most adults in primary prevention without established cardiovascular disease and without significant risk factors.

ApoB below 70 mg/dL is the target when significant risk factors are present: metabolic syndrome, a coronary artery calcium score above zero, diabetes mellitus, hypertension, or a family history of premature cardiovascular disease (first-degree relative with MI or coronary revascularization before age 55 in men, before age 65 in women).

ApoB below 55 mg/dL is the target for patients with established atherosclerotic cardiovascular disease: prior MI, prior stroke or TIA, peripheral artery disease, or any prior coronary revascularization procedure.

If your value sits above the target for your risk category, the next step is a direct conversation with your physician about whether your current lipid-lowering regimen, or the absence of one, matches the ApoB evidence base. In many cases, particularly when ApoB and LDL-C diverge significantly, the ApoB number changes what the clinically appropriate treatment plan looks like.

If your value sits above the target for your risk category, the next step is a direct conversation with your physician about whether your current lipid-lowering regimen, or the absence of one, matches the ApoB evidence base. In many cases, particularly when ApoB and LDL-C diverge significantly, the ApoB number changes what the clinically appropriate treatment plan looks like.

What Discordance Looks Like

The most clinically significant scenario is a patient with metabolic syndrome whose LDL-C reads as acceptable but whose ApoB reveals the particle burden that LDL-C is hiding. A man with a waist circumference above 40 inches, triglycerides of 220 mg/dL, HDL of 36 mg/dL, fasting glucose of 105 mg/dL, and LDL-C of 112 mg/dL sits below the typical treatment threshold in most US clinical algorithms based on LDL-C alone. His LDL-C of 112 generates no particular clinical urgency.

His ApoB, in this setting, is likely to be in the 130 to 145 mg/dL range, well above the 90 mg/dL threshold for primary prevention and potentially above the 70 mg/dL threshold appropriate for his risk factor burden. The gap between LDL-C of 112 and ApoB of 140 represents a large number of additional atherogenic particles that his standard panel is not counting.

The Canadian Dyslipidemia Working Group identified this pattern, calling it discordance, and found it to be most prevalent in exactly this metabolic phenotype: elevated triglycerides, low HDL, and only modestly elevated LDL-C. These patients are systematically undertreated when treatment decisions rest on LDL-C alone.

The converse also occurs: a patient on high-intensity statin therapy may have achieved an LDL-C of 58 mg/dL but an ApoB of 82 mg/dL, still above the 70 mg/dL target appropriate for his risk level. His LDL-C appears controlled; his ApoB indicates the treatment target has not been reached. Adding ezetimibe or a PCSK9 inhibitor to close that gap is a clinical decision that only becomes visible if ApoB is being measured.

A single ApoB measurement ordered at any blood draw, fasting or not, without scheduling a separate appointment or a separate needle stick, resolves this uncertainty. It either confirms that the particle burden matches what the LDL-C suggests, or it reveals a discordance that changes the clinical conversation. Either result is information. The absence of the test is not neutral; it is a gap in the cardiovascular risk assessment.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.